1. Home
  2. CCS vs SNDX Comparison

CCS vs SNDX Comparison

Compare CCS & SNDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Century Communities Inc.

CCS

Century Communities Inc.

HOLD

Current Price

$60.30

Market Cap

1.9B

ML Signal

HOLD

Logo Syndax Pharmaceuticals Inc.

SNDX

Syndax Pharmaceuticals Inc.

HOLD

Current Price

$19.53

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CCS
SNDX
Founded
2000
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Homebuilding
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.9B
1.7B
IPO Year
2014
2016

Fundamental Metrics

Financial Performance
Metric
CCS
SNDX
Price
$60.30
$19.53
Analyst Decision
Buy
Strong Buy
Analyst Count
5
12
Target Price
$70.50
$36.92
AVG Volume (30 Days)
240.3K
2.3M
Earning Date
01-28-2026
11-03-2025
Dividend Yield
1.92%
N/A
EPS Growth
N/A
N/A
EPS
6.93
N/A
Revenue
$4,157,669,000.00
$111,304,000.00
Revenue This Year
N/A
$620.14
Revenue Next Year
$8.74
$115.42
P/E Ratio
$8.73
N/A
Revenue Growth
N/A
595.65
52 Week Low
$50.42
$8.58
52 Week High
$88.41
$20.59

Technical Indicators

Market Signals
Indicator
CCS
SNDX
Relative Strength Index (RSI) 45.91 61.91
Support Level $63.69 $18.36
Resistance Level $67.10 $20.59
Average True Range (ATR) 2.10 0.99
MACD -0.03 0.05
Stochastic Oscillator 38.97 73.22

Price Performance

Historical Comparison
CCS
SNDX

About CCS Century Communities Inc.

Century Communities Inc is engaged in the development, design, construction, marketing, and selling of single-family attached and detached homes. It has five homebuilding segments: West, Mountain, Texas, Southeast, and Century Complete. Its sixth reportable segment is financial services operations, which provides mortgage, title, and insurance services to homebuyers. It has acquired land for homebuilding operations with the primary intent to develop and construct single-family detached or attached homes for sale on the acquired land. The company sells homes through its sales representatives and independent real estate brokers. The company generates the majority of its revenue from the Mountain segment.

About SNDX Syndax Pharmaceuticals Inc.

Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.

Share on Social Networks: